Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of secukinumab in ankylosing spondylitis (AS) and psoriatic arthritis (PsA)-comorbidities and extraarticular manifestations in Real world

Trial Profile

Study of secukinumab in ankylosing spondylitis (AS) and psoriatic arthritis (PsA)-comorbidities and extraarticular manifestations in Real world

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jun 2019 Interim results assessing efficacy in a subgroup of ankylosing spondylitis presented at the 20th Annual Congress of the European League Against Rheumatism.
    • 15 Jun 2019 Interim results assessing efficacy in a subgroup of psoriatic arthritis patients, presented at the 20th Annual Congress of the European League Against Rheumatism.
    • 24 Oct 2018 Interim results (n=486) evaluating the incidence of selected extraarticular manifestations and comorbidities at baseline and the impact of secukinumab on the status of these attributes compared to baseline, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top